



DT05 Rec'd PCT/PTO 07 OCT 2002  
13

I hereby certify that this correspondence is being deposited with the United States Postal Service on the date set forth below as First Class Mail in an envelope addressed to: Commissioner for Patents, Box Non-Fee, Washington, DC 20231.

Date of Signature and Deposit: September 30, 2002

Zhibin Ren

Zhibin Ren

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Richard J. Roman  
David R. Harder  
Noriyuki Miyata  
Masakazu Sato  
Kazuya Kameo  
Shigeru Okuyama

Date: September 30, 2002

Serial No.: 09/937,946

Group Art Unit:

Filed: October 2, 2001

Examiner:

Title: USE OF 20-HETE SYNTHESIZING ENZYME  
INHIBITORS AS THERAPY FOR CEREBRAL  
VASCULAR DISEASES

Docket No.: 650053.91533

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner For Patents  
Box Non-Fee  
Washington, DC 20231

Dear Sir:

Enclosed is a completed Form PTO-1449 listing additional documents that the applicant in the above-identified application wishes to bring to the attention of the Examiner for consideration in connection with the examination on the merits of this application. The documents were cited in the International Search Report in a corresponding PCT patent application. A copy of the International Research Report is enclosed for the Examiner's perusal.

No fee is believed due in connection with this submission. However, if a fee is due,  
please charge the fee to Deposit Account No. 17-0055.

Respectfully submitted,



---

Zhibin Ren  
Reg. No. 47,897  
Attorney for Applicants  
QUARLES & BRADY LLP  
P.O. Box 2113  
Madison, WI 53701-2113

TEL 608/251-5000  
FAX 608/251-9166

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



**Substitute for form 1449A/PTO**

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
*(use as many sheets as necessary)*

Sheet

1

10

1

Complaint Known	
Application Number	09/937,946
Filing Date	10/02/2001
First Named Inventor	Richard J. Roman
Group Art Unit	
Examiner Name	
Attorney Docket Number	650053.91533

## FOREIGN PATENT DOCUMENTS

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T *
		LANGE, et al., 20-Hydroxyeicosatetraenoic acid-induced vasoconstriction and inhibition of potassium current in cerebral vascular smooth muscle is dependent on activation of protein kinase C. J Biol Chem. 1997 Oct 24;272(43):27345-52.	
		ZOU, et al., Inhibition of renal vascular 20-HETE production impairs autoregulation of renal blood flow. Am J Physiol. 1994 Feb;266(No. 2 Pt 2):F275-82.	
		MIYATA, et al., HET006, a potent and selective inhibitor of 20-HETE synthesizing enzyme. Br J Pharmacol. 2001 Jun;133(3):325-9.	

EXAMINER SIGNATURE		DATE CONSIDERED	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231